# Palbociclib Mechanism of Action

##### How Palbociclib (Ibrance) Works: CDK4/6 inhibition that blocks progression from G1 into S phase.

Last updated: March 2026

## Quick Summary

Palbociclib (Ibrance) is a CDK4/6 inhibitor used for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with endocrine therapy. By inhibiting cyclin-dependent kinases 4 and 6, it blocks progression from the G1 phase into S phase of the cell cycle, helping suppress tumor proliferation.

### Properties

| Details                   |                                                    |
|---------------------------|----------------------------------------------------|
| **Generic Name**          | palbociclib                                        |
| **Brand Names**           | Ibrance                                           |
| **Drug Class**            | Kinase inhibitor (CDK4/6 inhibitor)               |
| **Primary Target**        | Cyclin-dependent kinase 4 (CDK4) / Cyclin-dependent kinase 6 (CDK6) |
| **Approved Indications**  | HR-positive (HR+), HER2-negative (HER2−) advanced or metastatic breast cancer in adults, in combination with an aromatase inhibitor (first-line) or fulvestrant (after prior endocrine therapy) |
| **Key Effect**            | Blocks cell-cycle progression from G1 to S by inhibiting CDK4/6, reducing tumor cell proliferation.

### Development History

Palbociclib was developed by [medicinal chemists at Pfizer Global Research and Development in Ann Arbor, Michigan](https://doi.org/10.1021/jm049354h). The pivotal program was anchored by [PALOMA-1/TRIO-18](https://doi.org/10.1016/S1470-2045(14)71159-3), a randomised phase 2 trial that compared palbociclib plus letrozole against letrozole alone. The results led to [FDA approval on February 3, 2015](https://www.pfizer.com/news/press-release/press-release-detail/ibrance_palbociclib_receives_fda_regular_approval_and_expanded_indication_for_first_line_hr_her2_metastatic_breast_cancer).

Label expansion followed with the phase 3 PALOMA-3 trial showing improved progression-free survival.

## Detailed Mechanism of Action

Palbociclib is absorbed orally and metabolized in the liver principally by [SULT2A1 and CYP3A](https://doi.org/10.3892/or.2018.6221). Its effectiveness arises from the inhibition of CDK4/6, preventing progress from G1 to S phase and causing tumor cell arrest.

### ATP-competitive inhibition of CDK4/6

Palbociclib targets the [CDK4/6 kinase core](https://doi.org/10.1016/j.phrs.2016.03.012) by occupying the ATP-binding cleft, forming hydrogen bonds with residues, resulting in potent activity against CDK4 and CDK6.

### Rb restriction-point blockade

In G1, palbociclib causes dephosphorylation of Rb, maintaining its repressive state. Phosphorylation history serves as a PD-0332991 activity biomarker, relevant for understanding resistance mechanisms in RB-deficient cells.

### E2F transcriptional suppression

By keeping Rb hypophosphorylated, palbociclib inhibits E2F transcription factors, suppressing downstream cell cycle progression.

### Clinical Relevance

Palbociclib is indicated for:

- **HR+/HER2− Advanced Breast Cancer:** Proven efficacy in combinations with both aromatase inhibitors and fulvestrant.
- **Emerging Indications:** Applications are being explored in other cancers, including Sarcoma and Gynecologic cancers.

### Key Drug Interactions

- **Strong CYP3A Inhibitors:** May increase palbociclib exposure.
- **Neutropenia Monitoring:** Occurs in 80-83% of patients.
- **Embryo-Fetal Toxicity:** Require effective contraception during treatment.

## Clinical Trials of Palbociclib

| Trial Name         | Phase | Indication                                         | Primary Endpoint                                    | Key Result                                                | Status  |
|-------------------|-------|---------------------------------------------------|----------------------------------------------------|----------------------------------------------------------|---------|
| PATINA            | 3     | HR+/HER2+ advanced breast cancer, first-line      | Progression-free survival (PFS)                     | Median PFS 44.3 vs 29.1 months; HR 0.74                  | Ongoing |
| PALOMA-2         | 3     | First-line ER+/HER2- advanced breast cancer       | Progression-free survival (PFS)                     | Median PFS 24.8 vs 14.5 months; HR 0.58                   | Completed |

## Emerging Indications

### Oncology — Gynecologic

- **Hormone Receptor-Positive Ovarian Cancer (Phase 2):** Promising results warranting further investigation.

## Open Research Questions

- What determines acquired palbociclib resistance mechanisms in tumors?
- How can palbociclib's immunomodulatory effects be utilized clinically?

This mechanism of action page was generated using Elicit's AI research agent, which synthesizes explanations from peer-reviewed pharmacology literature.